Sinclair says age-reversal gene therapy has moved into human eye trials

What was said

""And then the big thing is we've now gone into people. So there are people getting their hopefully their age reversed in their eye to cure their blindness or at least improve their vision at the very least.""

Harvard geneticist Dr David Sinclair says his team’s epigenetic “reprogramming” approach using a subset of Yamanaka factors has entered human testing, starting with the eye as a contained, safer site for gene therapy delivery. He describes the work as aimed at restoring vision in blindness, after animal results he says have been reproduced across multiple tissues and species.